Doramapimod is an anticancer chemotherapeutic inhibitor of p38 MAPK and JNK that also displays some in vitro activity against anaplastic lymphoma kinase (ALK). Doramapimod is currently in clinical trials as a potential treatment for inflammatory diseases, exhibiting anti-inflammatory activity. In vitro, this compound inhibits expression of COX-2, MMP13, iNOS, and TNF-α and decreases release of prostaglandin E2 (PGE2), decreasing the overall inflammatory response.

References


Caution: This product is intended for laboratory and research use only. It is not for human or drug use.